On January 9, 2014, Portola Pharmaceuticals announced the results of their phase III trial of intravenous Andexanet Alfa, an anti-Xa reversal agent. The trial, ANNEXA-R, tested Andexanet against rivaroxaban, however subsequent trials will generalize it to the additional anti-Xa‘s apixaban and edoxaban. Dave McGlasson comments and a January 9 article appears in The Heart, which mentions that Boehringer Ingelheim is also working on a reversal agent for dabigatran.
Jan 10 2015
Comments (1)Anticoagulant Therapy
Today in the money section of
Today in the money section of CNN, Porta Pharmaceuticals announced the initiation of a phase IV study to support accelerated approval of Andexanet Alfa anti-Xa reversal agent. I find it interesting that this comes almost one year after their releasing of their phase III study. Looks like they may have a winner to reverse the effects of a bleed caused by the anti-Xa TSOAC inhibitors.